Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 Jun;77(11):1732–1736. doi: 10.1038/bjc.1998.290

Multidrug resistance phenotype in leukaemic cells from patients with acute myelocytic leukaemia can be detected with 99Tc(m)-MIBI.

A Gruber 1, I Areström 1, D Xu 1, J Liliemark 1, S A Larsson 1, H Jacobsson 1
PMCID: PMC2150315  PMID: 9667640

Abstract

The aim of the study was to investigate whether 99Tc(m)-MIBI (Cardiolite), recently shown to be a substrate for P-glycoprotein, has the potential to be used as a marker for mdr1 gene expression and whether cyclosporin A (CyA) can modify its accumulation in vivo. Leukaemic cells from ten patients with acute myelocytic leukaemia (AML) were used, five with undetectable mdr1 gene expression and five with mdr1 mRNA levels ranging from 1.0 to 3.8 mdr1 mRNA transcripts per cell. Cells were incubated with 99Tc(m)-MIBI, or with daunorubicin (Dnr), with and without 3 microM CyA. The median 99Tc(m)-MIBI accumulation (% of added radioactivity) in mdr1-negative cells was 0.89% and in the mdr1-positive cells 0.34%, P = 0.01. In mdr1-negative cells, the median increase in 99Tc(m)-MIBI accumulation with CyA was 30% compared with the mdr1-positive cells with a median increase of 242%, P = 0.009. CyA had no significant effect on Dnr accumulation in four of the mdr1-negative samples. The median increase of Dnr accumulation in the mdr1-positive cells was 40%. The results show that 99Tc(m)-MIBI with a high sensitivity can detect rather low levels of mdr1 gene expression in clinical samples. Consequently, 99T(c)m-MIBI scintigraphy has the potential to be used for monitoring the effect of resistance modifiers on the accumulation and retention of cytostatic drugs in human tumours in vivo.

Full text

PDF
1732

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arao S., Suwa H., Mandai M., Tashiro H., Miyazaki K., Okamura H., Nomura H., Hiai H., Fukumoto M. Expression of multidrug resistance gene and localization of P-glycoprotein in human primary ovarian cancer. Cancer Res. 1994 Mar 1;54(5):1355–1359. [PubMed] [Google Scholar]
  2. Ballinger J. R., Hua H. A., Berry B. W., Firby P., Boxen I. 99Tcm-sestamibi as an agent for imaging P-glycoprotein-mediated multi-drug resistance: in vitro and in vivo studies in a rat breast tumour cell line and its doxorubicin-resistant variant. Nucl Med Commun. 1995 Apr;16(4):253–257. doi: 10.1097/00006231-199504000-00156. [DOI] [PubMed] [Google Scholar]
  3. Barrand M. A., Rhodes T., Center M. S., Twentyman P. R. Chemosensitisation and drug accumulation effects of cyclosporin A, PSC-833 and verapamil in human MDR large cell lung cancer cells expressing a 190k membrane protein distinct from P-glycoprotein. Eur J Cancer. 1993;29A(3):408–415. doi: 10.1016/0959-8049(93)90397-x. [DOI] [PubMed] [Google Scholar]
  4. Baurain R., Zenebergh A., Trouet A. Cellular uptake and metabolism of daunorubicin as determined by high-performance liquid chromatography. Application to L1210 cells. J Chromatogr. 1978 Sep 21;157:331–336. doi: 10.1016/s0021-9673(00)92350-1. [DOI] [PubMed] [Google Scholar]
  5. Broxterman H. J., Sonneveld P., Feller N., Ossenkoppele G. J., Währer D. C., Eekman C. A., Schoester M., Lankelma J., Pinedo H. M., Löwenberg B. Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity. Blood. 1996 Jun 1;87(11):4809–4816. [PubMed] [Google Scholar]
  6. Campos L., Guyotat D., Archimbaud E., Calmard-Oriol P., Tsuruo T., Troncy J., Treille D., Fiere D. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood. 1992 Jan 15;79(2):473–476. [PubMed] [Google Scholar]
  7. Cole S. P., Bhardwaj G., Gerlach J. H., Mackie J. E., Grant C. E., Almquist K. C., Stewart A. J., Kurz E. U., Duncan A. M., Deeley R. G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 1992 Dec 4;258(5088):1650–1654. doi: 10.1126/science.1360704. [DOI] [PubMed] [Google Scholar]
  8. Fojo A. T. Multidrug resistance. Adv Intern Med. 1991;36:195–218. [PubMed] [Google Scholar]
  9. Goldstein L. J., Pastan I., Gottesman M. M. Multidrug resistance in human cancer. Crit Rev Oncol Hematol. 1992;12(3):243–253. doi: 10.1016/1040-8428(92)90057-w. [DOI] [PubMed] [Google Scholar]
  10. Gruber A., Vitols S., Norgren S., Areström I., Peterson C., Björkholm M., Reizenstein P., Luthman H. Quantitative determination of mdr1 gene expression in leukaemic cells from patients with acute leukaemia. Br J Cancer. 1992 Aug;66(2):266–272. doi: 10.1038/bjc.1992.255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hart S. M., Ganeshaguru K., Hoffbrand A. V., Prentice H. G., Mehta A. B. Expression of the multidrug resistance-associated protein (MRP) in acute leukaemia. Leukemia. 1994 Dec;8(12):2163–2168. [PubMed] [Google Scholar]
  12. Ino T., Miyazaki H., Isogai M., Nomura T., Tsuzuki M., Tsuruo T., Ezaki K., Hirano M. Expression of P-glycoprotein in de novo acute myelogenous leukemia at initial diagnosis: results of molecular and functional assays, and correlation with treatment outcome. Leukemia. 1994 Sep;8(9):1492–1497. [PubMed] [Google Scholar]
  13. Kapucu L. O., Akyüz C., Vural G., Oguz A., Atasever T., Büyükpamukçu M., Unlü M. Evaluation of therapy response in children with untreated malignant lymphomas using technetium-99m-sestamibi. J Nucl Med. 1997 Feb;38(2):243–247. [PubMed] [Google Scholar]
  14. Lee P. D., Noble-Topham S. E., Bell R. S., Andrulis I. L. Quantitative analysis of multidrug resistance gene expression in human osteosarcomas. Br J Cancer. 1996 Oct;74(7):1046–1050. doi: 10.1038/bjc.1996.487. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Leith C. P., Kopecky K. J., Godwin J., McConnell T., Slovak M. L., Chen I. M., Head D. R., Appelbaum F. R., Willman C. L. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood. 1997 May 1;89(9):3323–3329. [PubMed] [Google Scholar]
  16. Linn S. C., Honkoop A. H., Hoekman K., van der Valk P., Pinedo H. M., Giaccone G. p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer. Br J Cancer. 1996 Jul;74(1):63–68. doi: 10.1038/bjc.1996.316. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. List A. F., Spier C., Greer J., Wolff S., Hutter J., Dorr R., Salmon S., Futscher B., Baier M., Dalton W. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol. 1993 Sep;11(9):1652–1660. doi: 10.1200/JCO.1993.11.9.1652. [DOI] [PubMed] [Google Scholar]
  18. Luker G. D., Fracasso P. M., Dobkin J., Piwnica-Worms D. Modulation of the multidrug resistance P-glycoprotein: detection with technetium-99m-sestamibi in vivo. J Nucl Med. 1997 Mar;38(3):369–372. [PubMed] [Google Scholar]
  19. Miller T. P., Grogan T. M., Dalton W. S., Spier C. M., Scheper R. J., Salmon S. E. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol. 1991 Jan;9(1):17–24. doi: 10.1200/JCO.1991.9.1.17. [DOI] [PubMed] [Google Scholar]
  20. Moretti J. L., Azaloux H., Boisseron D., Kouyoumdjian J. C., Vilcoq J. Primary breast cancer imaging with technetium-99m sestamibi and its relation with P-glycoprotein overexpression. Eur J Nucl Med. 1996 Aug;23(8):980–986. doi: 10.1007/BF01084375. [DOI] [PubMed] [Google Scholar]
  21. Piwnica-Worms D., Chiu M. L., Budding M., Kronauge J. F., Kramer R. A., Croop J. M. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res. 1993 Mar 1;53(5):977–984. [PubMed] [Google Scholar]
  22. Piwnica-Worms D., Rao V. V., Kronauge J. F., Croop J. M. Characterization of multidrug resistance P-glycoprotein transport function with an organotechnetium cation. Biochemistry. 1995 Sep 26;34(38):12210–12220. doi: 10.1021/bi00038a015. [DOI] [PubMed] [Google Scholar]
  23. Raderer M., Scheithauer W. Clinical trials of agents that reverse multidrug resistance. A literature review. Cancer. 1993 Dec 15;72(12):3553–3563. doi: 10.1002/1097-0142(19931215)72:12<3553::aid-cncr2820721203>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  24. Sarris A. H., Younes A., McLaughlin P., Moore D., Hagemeister F., Swan F., Rodriguez M. A., Romaguera J., North L., Mansfield P. Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol. 1996 Jan;14(1):233–239. doi: 10.1200/JCO.1996.14.1.233. [DOI] [PubMed] [Google Scholar]
  25. Schneider E., Cowan K. H., Bader H., Toomey S., Schwartz G. N., Karp J. E., Burke P. J., Kaufmann S. H. Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood. 1995 Jan 1;85(1):186–193. [PubMed] [Google Scholar]
  26. Sonneveld P., Durie B. G., Lokhorst H. M., Marie J. P., Solbu G., Suciu S., Zittoun R., Löwenberg B., Nooter K. Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON. Lancet. 1992 Aug 1;340(8814):255–259. doi: 10.1016/0140-6736(92)92353-h. [DOI] [PubMed] [Google Scholar]
  27. Vecchio S. D., Ciarmiello A., Potena M. I., Carriero M. V., Mainolfi C., Botti G., Thomas R., Cerra M., D'Aiuto G., Tsuruo T. In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients. Eur J Nucl Med. 1997 Feb;24(2):150–159. doi: 10.1007/BF02439547. [DOI] [PubMed] [Google Scholar]
  28. Xu D., Knaust E., Pisa P., Palucka K., Lundeberg J., Areström I., Peterson C., Gruber A. Levels of mdr1 and mrp mRNA in leukaemic cell populations from patients with acute myelocytic leukaemia are heterogenous and inversely correlated to cellular daunorubicin accumulation. Br J Haematol. 1996 Mar;92(4):847–854. doi: 10.1046/j.1365-2141.1996.425963.x. [DOI] [PubMed] [Google Scholar]
  29. Yuen A. R., Sikic B. I. Multidrug resistance in lymphomas. J Clin Oncol. 1994 Nov;12(11):2453–2459. doi: 10.1200/JCO.1994.12.11.2453. [DOI] [PubMed] [Google Scholar]
  30. te Boekhorst P. A., Löwenberg B., van Kapel J., Nooter K., Sonneveld P. Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia. Leukemia. 1995 Jun;9(6):1025–1031. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES